Microplate Dx Limited

Microplate Dx has developed and validated a rapid, affordable, AST platform, 'RapidPlate' which performs AST directly from patient samples and provides personalised recommendations of appropriate antibiotics to use for bacterial or fungal infections, all <1 hour. RapidPlate comprises a benchtop instrument (reader) with measurement electronics, software, and readout. Test cartridge consumables, featuring multiple hydrogel-modified electrode sensors, laden with different antibiotics to develop electrochemical growth profiles from samples, complete the novel system. RapidPlate is a scalable platform technology: following first deployment to provide treatment guidance for urinary tract infections (UTIs) in a timely targeted manner, it has significant potential to scale to a range of other bacterial and fungal infections according to market need.